These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22517723)

  • 1. Docetaxel nanotechnology in anticancer therapy.
    Zhao P; Astruc D
    ChemMedChem; 2012 Jun; 7(6):952-72. PubMed ID: 22517723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
    Feng SS; Mei L; Anitha P; Gan CW; Zhou W
    Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulation of docetaxel into PEGylated gold nanoparticles for vectorization to cancer cells.
    François A; Laroche A; Pinaud N; Salmon L; Ruiz J; Robert J; Astruc D
    ChemMedChem; 2011 Nov; 6(11):2003-8. PubMed ID: 21834092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancer.
    Llevot A; Astruc D
    Chem Soc Rev; 2012 Jan; 41(1):242-57. PubMed ID: 21785769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
    Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
    J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macromolecules as taxane delivery systems.
    Dosio F; Stella B; Arpicco S; Cattel L
    Expert Opin Drug Deliv; 2011 Jan; 8(1):33-55. PubMed ID: 21142695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How nanotechnology can enhance docetaxel therapy.
    Zhang L; Zhang N
    Int J Nanomedicine; 2013; 8():2927-41. PubMed ID: 23950643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
    Sohail MF; Rehman M; Sarwar HS; Naveed S; Salman O; Bukhari NI; Hussain I; Webster TJ; Shahnaz G
    Int J Nanomedicine; 2018; 13():3145-3161. PubMed ID: 29922053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.
    Reddy LH; Bazile D
    Adv Drug Deliv Rev; 2014 May; 71():34-57. PubMed ID: 24184489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly efficient system to deliver taxanes into tumor cells: docetaxel-loaded chitosan oligomer colloidal carriers.
    Lozano MV; Torrecilla D; Torres D; Vidal A; Domínguez F; Alonso MJ
    Biomacromolecules; 2008 Aug; 9(8):2186-93. PubMed ID: 18637687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative drug formulations of docetaxel: a review.
    Engels FK; Mathot RA; Verweij J
    Anticancer Drugs; 2007 Feb; 18(2):95-103. PubMed ID: 17159596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
    Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
    J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes.
    Gaucher G; Marchessault RH; Leroux JC
    J Control Release; 2010 Apr; 143(1):2-12. PubMed ID: 19925835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The scientific rationale for developing taxoids.
    Aapro M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocarriers for anticancer drugs--new trends in nanomedicine.
    Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
    Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy.
    Prakash S; Malhotra M; Shao W; Tomaro-Duchesneau C; Abbasi S
    Adv Drug Deliv Rev; 2011 Nov; 63(14-15):1340-51. PubMed ID: 21756952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxane anticancer agents: a patent perspective.
    Ojima I; Lichtenthal B; Lee S; Wang C; Wang X
    Expert Opin Ther Pat; 2016; 26(1):1-20. PubMed ID: 26651178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical nanotechnology for oral delivery of anticancer drugs.
    Mei L; Zhang Z; Zhao L; Huang L; Yang XL; Tang J; Feng SS
    Adv Drug Deliv Rev; 2013 Jun; 65(6):880-90. PubMed ID: 23220325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid lipid nanoparticles reduce systemic toxicity of docetaxel: performance and mechanism in animal.
    Gao Y; Yang R; Zhang Z; Chen L; Sun Z; Li Y
    Nanotoxicology; 2011 Dec; 5(4):636-49. PubMed ID: 21306192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.